Eplerenone

證據等級: L5

預測適應症: 5 個

Eplerenone: From Hypertension to Pulmonary Hypertension (Unclear Multifactorial Mechanism)

One-Sentence Summary

Eplerenone is an aldosterone (mineralocorticoid receptor) antagonist internationally known for hypertension and heart failure; it is not currently marketed in Taiwan and detailed original-indication/MOA data are not present in this evidence pack. The TxGNN model predicts possible efficacy in Pulmonary Hypertension with Unclear Multifactorial Mechanism (WHO Group 5 PH), but this ranking is supported by 0 clinical trials and 0 publications — it is a pure algorithmic prediction with no corroborating evidence.

Quick Overview

Item	Content
Original Indication	Not available from Taiwan regulatory data (drug not marketed locally); internationally known as an aldosterone/mineralocorticoid receptor antagonist used for hypertension and heart failure
Predicted New Indication	Pulmonary Hypertension with Unclear Multifactorial Mechanism (WHO Group 5 PH)
TxGNN Prediction Score	99.50%
Evidence Level	L5
US Market Status	Not Marketed (Taiwan)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on general pharmacological knowledge, eplerenone is a selective mineralocorticoid (aldosterone) receptor antagonist, a mechanism proven effective in hypertension and post-MI heart failure by inhibiting downstream RAAS/aldosterone signaling.

WHO Group 5 pulmonary hypertension is defined precisely by unclear or multifactorial mechanisms, spanning conditions as diverse as hematologic disorders, metabolic disease, and systemic disorders. Because this disease category has no single, well-characterized pathophysiology, there is no established biological rationale linking aldosterone antagonism to this specific PH subtype in the evidence provided.

The source rationale explicitly states that this candidate has no clinical trials, no literature, and no constructible mechanistic hypothesis — it is flagged as a pure knowledge-graph inference rather than a biologically grounded hypothesis. This should be treated as a hypothesis-generation signal only, not as evidence of therapeutic plausibility.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

(Note: A TFDA label/warnings data gap is flagged as Blocking in this evidence pack — package insert data for eplerenone has not yet been retrieved, so no S1 safety screening has occurred.)

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate is evidence level L5 (model prediction only) with zero supporting clinical trials or literature, and no mechanistic hypothesis could be constructed linking eplerenone to this PH subtype. Additionally, a Blocking data gap exists for TFDA label/warning information, which prevents any safety pre-screening.

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) — currently a Blocking data gap
Confirmed original MOA and indication data from DrugBank or TFDA — currently a High-severity data gap
Any preclinical or mechanistic studies specifically linking mineralocorticoid receptor antagonism to Group 5 PH pathophysiology
Re-query clinical trial and literature databases targeting eplerenone + pulmonary hypertension directly (current searches returned 0 results for this specific candidate)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.